TAT 2021 - 19th International Congress On Targeted Anticancer Therapies (Virtual Meeting)
Mar 01 - Mar 02, 2021 | ParisFrance
LARVOL is not affiliated with 19th International Congress On Targeted Anticancer Therapies (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 13 abstracts linked to Trials
[VIRTUAL] Updated results from phase 1 study of CC-90011 in patients (pts) with solid tumors (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
[VIRTUAL] First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with Advanced non-small cell lung cancer (NSCLC)
[VIRTUAL] Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses followed by Dose Expansion of selinexor in Asian Patients with Advanced Solid Tumor Malignancies.
[VIRTUAL] CC-90010, a Reversible, Potent Oral Bromodomain and Extraterminal Inhibitor (BETi) in Patients (pts) with Advanced Solid Tumors (aSTs) and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Longer Follow-Up From Parts A & B and First Reporting of Part C of a Phase 1 Study
[VIRTUAL] Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: a phase 1b study in patients with advanced gastric cancer (RPT835GC1B)
[VIRTUAL] Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumors and superficial lesions
[VIRTUAL] A phase I study to evaluate safety, pharmacokinetics (PK), and preliminary efficacy of CYH33, a phosphatidylinositol 3-kinase α (PI3Kα) inhibitor, in patients (pts) with advanced solid tumors
[VIRTUAL] Immunohybridoma Cell-Based Vaccine for the Treatment of Patients with Castration-Resistant Prostate Cancer
[VIRTUAL] Safety, Tolerability and Preliminary Efficacy of Poziotinib with Twice Daily Strategy in EGFR/HER2 Exon 20 Mutant Non-small Cell Lung Cancer
[VIRTUAL] IND.236: A Canadian Cancer Trial Group (CCTG) Phase 1b trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)
[VIRTUAL] Immunohybridoma Cell-Based Vaccine for the Treatment of Patients with Castration-Resistant Prostate Cancer
[VIRTUAL] Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: a phase 1b study in patients with advanced gastric cancer (RPT835GC1B)
[VIRTUAL] Outcomes according to FGFR alteration types in patients with a solid tumor treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials.